VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Methylenedioxymethamphetamine (“MDMA”) and…


Previous articlePsychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces Take-Private Deal; Compass Patents Upheld; Theories of Psychedelics’ Mechanism of Action
Next articleIbogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course